Saadet Nurşah Gedikli

Saadet Nurşah Gedikli

Auto-generated profile, based on publicly available information

Saadet Nurşah Gedikli

Department of Dermatology, University of Health Sciences, Kayseri City Education and Research Hospital, Kayseri, Türkiye

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2025 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
EÜEsranur Ünal
Esranur Ünal
MYMuhammed Burak Yücel
Muhammed Burak Yücel
SGSaadet Nurşah Gedikli
Saadet Nurşah Gedikli
YUYılmaz Ulaş
Yılmaz Ulaş
FMFatma Türkan Mutlu
Fatma Türkan Mutlu
BABengu Nisa Nisa Akay
Bengu Nisa Nisa Akay

8 December 2025 in Cutaneous and Ocular Toxicology
Verified
Journal Article
Closed access
EÜEsranur Ünal
Esranur Ünal
MYMuhammed Burak Yücel
Muhammed Burak Yücel
SGSaadet Nurşah Gedikli
Saadet Nurşah Gedikli
BABengu Nisa Nisa Akay
Bengu Nisa Nisa Akay
The global incidence of skin cancer is rising, emphasizing the need for early detection tools. Artificial intelligence (AI) models, including multimodal systems like ChatGPT-4o, can analyze visual data to assist clinicians in diagnosis. This study evaluated ChatGPT-4o's diagnostic accuracy in detecting melanoma and non-melanoma skin cancers from macroscopic and dermoscopic images. Ninety patients with histopathologically confirmed lesions were included. For each patient, macroscopic images were first uploaded to ChatGPT-4o, followed by combined upload of macroscopic and dermoscopic images. ChatGPT-4o was instructed to provide a preliminary diagnosis and three differential diagnoses for each lesion. Accuracy was assessed at four levels: Level 1: preliminary diagnosis using macroscopic images; Level 2: preliminary diagnosis using macroscopic and dermoscopic images; Level 3: three differential diagnoses using macroscopic images; Level 4: three differential diagnoses using macroscopic and dermoscopic images. Overall Level 1 accuracy was 73.3%, with Level 2, Level 3, and Level 4 accuracies of 66.6%, 75%, and 76.6%, respectively. Dermoscopic images improved accuracy for squamous cell carcinoma (72.7% vs 81.8%, p = 1.00), reduced overall and basal cell carcinoma accuracy (73.3% vs 66.6%, p = 0.180 and 79.6% vs 67.8%, p = 0.065, respectively), and did not affect malignant melanoma (84.6% vs 84.6%) or lentigo maligna (0% vs 0%). Statistical analysis revealed that the addition of dermoscopic images did not significantly influence diagnostic accuracy, either overall or within individual diagnostic categories. The model recommended biopsy for all lesions, suggesting potential as a supportive diagnostic tool. ChatGPT-4o showed variable diagnostic accuracy for melanoma and non-melanoma skin cancers. Dermoscopic images reduced performance for certain diagnostic categories. These misclassifications highlight the potential for unnecessary interventions and patient anxiety underscoring that AI-based systems should serve as supportive aids rather than standalone diagnostic tools.

4 March 2026 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
EÜEsranur Ünal
Esranur Ünal
BPBeste Pakırdaşı
Beste Pakırdaşı
SESelma Emre
Selma Emre
MYMuhammed Burak Yücel
Muhammed Burak Yücel
BCBurak Celik
Burak Celik
OYOrhan Yıldız
Orhan Yıldız
Real-world evidence regarding biologic therapy in geriatric psoriasis is limited, particularly concerning systemic inflammatory burden and infection-related safety. This study evaluates the clinical efficacy of biologic therapy and its impact on systemic inflammatory indices while emphasizing safety related to hepatitis B virus (HBV) serology and tuberculosis screening. We conducted a retrospective analysis of eighty biologic-naïve patients aged 65 years and older with plaque psoriasis undergoing biologic therapy. Patients were categorized by biologic class: tumor necrosis factor-α (TNF-α) inhibitors, interleukin-17 inhibitors, an interleukin-12/23 inhibitor, and interleukin-23 inhibitors. The primary outcomes included changes in Psoriasis Area and Severity Index (PASI) scores and blood count-derived inflammatory indices over time (baseline and 6 months). Secondary outcomes encompassed changes in HBV serologic status and QuantiFERON-TB (QFT) results. Data analysis utilized longitudinal mixed-effects models for repeated measures. Blood count-derived inflammatory indices, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), were assessed at baseline and 6 months, alongside HBV serology and QFT results. PASI scores demonstrated significant improvement over time (p < 0.001), with no notable differences among biologic classes after adjusting for baseline covariates. Significant time effects were observed for all inflammatory indices (all p < 0.001), with significant group × time interactions noted for SII and NLR (both p < 0.05). Variability in HBV serologic markers and QFT results was observed during follow-up; however, no cases of active tuberculosis or clinically overt hepatitis were identified. In conclusion, biologic therapy led to substantial clinical improvement in geriatric psoriasis, accompanied by reductions in systemic inflammatory indices over a 6-month period, without evidence of clinically overt hepatitis or active tuberculosis during follow-up.

30 April 2025 in Abant Medical Journal
Verified
Journal Article
Open access
PDF file
EÜEsranur Ünal
Esranur Ünal
SGSaadet Nurşah Gedikli
Saadet Nurşah Gedikli
FŞFatma Şenel
Fatma Şenel
MYMuhammed Burak Yücel
Muhammed Burak Yücel
COVID-19 vaccines may cause the onset or exacerbation of inflammatory skin diseases. However, the relationship between COVID-19 vaccines and immune-mediated skin diseases is still not fully known. Lichen planus pigmentosus inversus is a rare variant of lichen planus and, unlike lichen planus pigmentosus, this form affects people with white skin. It occurs in intertriginous areas such as the groin and axillae and 90% of patients have axillary involvement. There are cases of lichen planus reported after COVID-19 vaccines, and this is the first case of lichen planus pigmentosus inversus after SARS‐CoV‐2 vaccine (Sinovac). Additional studies are needed to demonstrate this relationship.